Sanctuary Advisors LLC Purchases 1,917 Shares of Natera, Inc. $NTRA

Sanctuary Advisors LLC increased its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 12.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 17,820 shares of the medical research company’s stock after buying an additional 1,917 shares during the quarter. Sanctuary Advisors LLC’s holdings in Natera were worth $3,564,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Horizon Investments LLC raised its holdings in Natera by 22.0% during the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after buying an additional 44 shares during the period. Sound Income Strategies LLC raised its holdings in shares of Natera by 20.0% during the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after acquiring an additional 45 shares during the period. Savvy Advisors Inc. raised its holdings in shares of Natera by 3.1% during the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after acquiring an additional 46 shares during the period. First Horizon Corp lifted its position in Natera by 5.5% in the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock valued at $196,000 after acquiring an additional 51 shares in the last quarter. Finally, Siemens Fonds Invest GmbH boosted its stake in Natera by 3.1% in the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after purchasing an additional 54 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

NTRA has been the topic of a number of research reports. Morgan Stanley boosted their price target on Natera from $250.00 to $310.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Wall Street Zen lowered Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. TD Cowen restated a “buy” rating on shares of Natera in a research note on Wednesday. Zacks Research downgraded Natera from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Finally, Royal Bank Of Canada assumed coverage on shares of Natera in a research note on Thursday, June 11th. They set an “outperform” rating and a $275.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $267.83.

Natera Stock Performance

NTRA opened at $271.39 on Monday. Natera, Inc. has a 52-week low of $131.81 and a 52-week high of $288.04. The firm has a market capitalization of $38.87 billion, a PE ratio of -166.50 and a beta of 1.51. The business’s 50-day simple moving average is $233.97 and its 200 day simple moving average is $220.33.

Insider Activity

In other news, Director Roelof Botha sold 78,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the sale, the director owned 1,076,198 shares in the company, valued at $237,097,181.38. This represents a 6.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Solomon Moshkevich sold 3,405 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $203.69, for a total value of $693,564.45. Following the sale, the insider owned 142,295 shares in the company, valued at approximately $28,984,068.55. This represents a 2.34% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 178,872 shares of company stock worth $39,627,696. Corporate insiders own 5.05% of the company’s stock.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.